BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
BioNxt Solutions (BNXTF) has received formal notice from the European Patent Office (EPO) of their intention to grant the company's core patent for sublingual delivery of anticancer drugs treating autoimmune neurodegenerative diseases. The patent is particularly significant for BNT23001, their lead product - a sublingual thin-film formulation of Cladribine designed to treat multiple sclerosis (MS).
The company is advancing patent protection through the EPO, Eurasian Patent Organization, and independent nations including Australia, Canada, New Zealand, USA, and Japan. This intellectual property will support BioNxt's pipeline of sublingual products targeting various autoimmune diseases including MS, myasthenia gravis, lupus nephritis, and rheumatoid arthritis.
BioNxt Solutions (BNXTF) ha ricevuto una comunicazione ufficiale dall'Ufficio Brevetti Europeo (EPO) riguardo all'intenzione di concedere il brevetto principale dell'azienda per la somministrazione sublinguale di farmaci anticancro per il trattamento di malattie neurodegenerative autoimmuni. Il brevetto è particolarmente rilevante per BNT23001, il loro prodotto di punta - una formulazione a film sottile sublinguale di Cladribina progettata per trattare la sclerosi multipla (SM).
L'azienda sta estendendo la protezione brevettuale attraverso l'EPO, l'Organizzazione dei Brevetti Eurasiatica e paesi indipendenti come Australia, Canada, Nuova Zelanda, USA e Giappone. Questa proprietà intellettuale sosterrà la pipeline di BioNxt di prodotti sublinguali mirati a diverse malattie autoimmuni tra cui SM, miastenia gravis, lupus nefritico e artrite reumatoide.
BioNxt Solutions (BNXTF) ha recibido una notificación formal de la Oficina Europea de Patentes (EPO) sobre su intención de conceder la patente principal de la empresa para la administración sublingual de fármacos anticancerígenos que tratan enfermedades neurodegenerativas autoinmunes. La patente es especialmente importante para BNT23001, su producto principal, una formulación de película delgada sublingual de Cladribina diseñada para tratar la esclerosis múltiple (EM).
La empresa está avanzando en la protección de la patente a través de la EPO, la Organización de Patentes Euroasiática y países independientes como Australia, Canadá, Nueva Zelanda, EE.UU. y Japón. Esta propiedad intelectual respaldará la cartera de productos sublinguales de BioNxt dirigidos a diversas enfermedades autoinmunes, incluyendo EM, miastenia gravis, lupus nefrítico y artritis reumatoide.
BioNxt Solutions (BNXTF)는 유럽 특허청(EPO)으로부터 자가면역 신경퇴행성 질환 치료를 위한 항암제 설하 투여 핵심 특허를 부여할 의향이 있다는 공식 통지를 받았습니다. 이 특허는 다발성 경화증(MS) 치료를 위해 설계된 클라드리빈의 설하 박막 제형인 BNT23001에 특히 중요합니다.
회사는 EPO, 유라시아 특허기구 및 호주, 캐나다, 뉴질랜드, 미국, 일본 등 독립 국가들을 통해 특허 보호를 확대하고 있습니다. 이 지적 재산권은 MS, 중증근무력증, 루푸스 신염, 류마티스 관절염 등 다양한 자가면역 질환을 타깃으로 하는 BioNxt의 설하 제품 파이프라인을 지원할 것입니다.
BioNxt Solutions (BNXTF) a reçu une notification officielle de l'Office Européen des Brevets (OEB) concernant leur intention d'accorder le brevet principal de la société pour l'administration sublinguale de médicaments anticancéreux traitant les maladies neurodégénératives auto-immunes. Ce brevet est particulièrement important pour BNT23001, leur produit phare – une formulation en film mince sublingual de Cladribine conçue pour traiter la sclérose en plaques (SEP).
L'entreprise fait progresser la protection de ses brevets via l'OEB, l'Organisation Eurasienne des Brevets, ainsi que dans des pays indépendants tels que l'Australie, le Canada, la Nouvelle-Zélande, les États-Unis et le Japon. Cette propriété intellectuelle soutiendra la gamme de produits sublinguaux de BioNxt ciblant diverses maladies auto-immunes, notamment la SEP, la myasthénie grave, le lupus néphritique et la polyarthrite rhumatoïde.
BioNxt Solutions (BNXTF) hat vom Europäischen Patentamt (EPA) eine formelle Mitteilung über die Absicht erhalten, das Kernpatent des Unternehmens für die sublinguale Verabreichung von Krebsmedikamenten zur Behandlung von Autoimmun-Neurodegenerativen Erkrankungen zu erteilen. Das Patent ist besonders wichtig für BNT23001, ihr führendes Produkt – eine sublinguale Dünnfilmformulierung von Cladribin zur Behandlung von Multipler Sklerose (MS).
Das Unternehmen erweitert den Patentschutz über das EPA, die Eurasische Patentorganisation sowie unabhängige Länder wie Australien, Kanada, Neuseeland, USA und Japan. Dieses geistige Eigentum wird BioNxts Pipeline von sublingualen Produkten unterstützen, die verschiedene Autoimmunerkrankungen wie MS, Myasthenia gravis, Lupusnephritis und rheumatoide Arthritis ansprechen.
- Imminent grant of core patent in Europe for sublingual drug delivery technology
- Patent protection extends to multiple autoimmune disease treatments
- Strategic timing aligns with upcoming BNT23001 human bioequivalence study
- Global patent protection process advancing in multiple key markets
- None.
VANCOUVER, BC / ACCESS Newswire / May 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the examining division of the European Patent Office ("EPO") has provided formal notice of the EPO's intention to grant BioNxt its core patent without significant changes.
The Company's core patent filing was a comprehensive application for the sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases. This patent family provides numerous proprietary product development and commercialization opportunities, including BioNxt's lead product, BNT23001, a sublingual thin-film formulation of Cladribine for the treatment of multiple sclerosis (MS).
"Confirmation of the Company's flagship intellectual property asset in Europe is a major milestone for BioNxt," stated Hugh Rogers, CEO of BioNxt. "We expect the European patent grant to be finalized and published in the coming weeks. The timing is excellent as we can confidently prepare for the upcoming BNT23001 human bioequivalence study in Europe."
BioNxt continues to advance the nationalization phase of the patent protection process at the European Patent Office and Eurasian Patent Organization, as well as with independent filing nations, such as Australia (AU), Canada (CA), New Zealand (NZ), USA (US), and Japan (JP). Securing nation-level patents around the globe will serve as the foundation for commercial opportunities for the Company's pipeline of sublingual products targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA).
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
FAQ
What patent did BioNxt Solutions (BNXTF) receive notice for from the European Patent Office?
What is BioNxt's (BNXTF) lead product BNT23001?
Which countries is BioNxt Solutions pursuing patent protection in?
What autoimmune diseases will BioNxt's sublingual product pipeline target?
